A5064230008- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Urologic and reproductive health conditions
- Testicular diseases and treatments
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Lung Cancer Treatments and Mutations
- Hormonal and reproductive studies
- Sarcoma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Economic and Financial Impacts of Cancer
- Cancer Research and Treatments
- Infectious Disease Case Reports and Treatments
- Urinary Bladder and Prostate Research
- Ethics in Clinical Research
- Gastric Cancer Management and Outcomes
- Tissue Engineering and Regenerative Medicine
- Health Systems, Economic Evaluations, Quality of Life
- Cancer, Hypoxia, and Metabolism
- Renal and related cancers
- Genital Health and Disease
Rowan University
2013-2025
New Jersey Urology
2016-2025
Delaware Valley College
2015-2024
Jefferson College
2024
Thomas Jefferson University Hospital
2024
Fred Hutch Cancer Center
2022
University of Washington
2022
Philadelphia College of Osteopathic Medicine
2021
NHS Greater Glasgow and Clyde
2018
The University of Texas MD Anderson Cancer Center
2005-2013
Overdiagnosis and overtreatment of indolent prostate cancer (PCA) is a serious health issue in most developed countries. There an unmet clinical need for noninvasive, easy to administer, diagnostic assays help assess whether biopsy warranted.To determine the performance novel urine exosome gene expression assay (the ExoDx Prostate IntelliScore assay) plus standard care (SOC) (ie, prostate-specific antigen [PSA] level, age, race, family history) vs SOC alone discriminating between Gleason...
Discriminating indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical adoption. Performance utility assessment of ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay versus standard parameters for discriminating Grade Group (GG) ≥2 PCa GG1 benign disease on biopsy. A two-phase adaptive study (NCT03031418) comparing EPI...
Open AccessJournal of UrologyAdult Urology5 May 2024Efficacy Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non–muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial Vikram M. Narayan, Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, Joseph E. Busby, Michael Poch, Paul L. Crispen, Gary Steinberg, Anne K. Schuckman, Tracy Downs,...
Abstract BACKGROUND: The authors evaluated the incidence of pathologic downstaging and complete remission (CR) in patients with high‐grade ureteral renal pelvic transitional cell carcinoma (TCC) (upper tract TCC) who received neoadjuvant chemotherapy followed by surgery. METHODS: study group comprised biopsy‐demonstrated, disease nephrouterectomy from 2004 to 2008, during which time uniformly were considered for chemotherapy. control underwent initial nephroureterectomy 1993 2004, when...
Sarcomatoid carcinoma and carcinosarcoma of the bladder are rare tumors that contain epithelial mesenchymal elements, may portend a worse prognosis than conventional urothelial carcinoma. We investigated survival patients with 2 tumor subtypes compared to in those carcinoma.Cases sarcomatoid carcinoma, high grade were identified from Surveillance, Epidemiology End Results Program. Demographic pathological characteristics compared. Differences based on histological subtype estimated using...
To compare the utility of lymph node density (LND) with TNM nodal status in predicting disease-specific survival (DSS) after radical cystectomy.We identified 248 patients metastasis cystectomy (without neoadjuvant chemotherapy): 162 from Memorial Sloan-Kettering Cancer Center (MSKCC) and 86 M.D. Anderson (MDACC). We assessed effect several variables on DSS.After a median follow-up duration 24 months, 134 died their disease. The DSS was 36 1-year, 2-year, 5-year rates were 83.7%, 57.4%,...
OBJECTIVE To evaluate factors associated with disease recurrence and survival in patients undergoing nephroureterectomy for upper urinary tract transitional cell carcinoma (UUT‐TCC) one centre over an 18‐year period. PATIENTS AND METHODS The records of who had a UUT‐TCC at our institution from 1986 to 2004 were reviewed clinical, pathological treatment period data. Cox’s proportional hazards regression model was used test the statistical significance several potential prognostic survival....
Epidermal growth factor receptor (EGFR) is an attractive target for the treatment of urothelial carcinoma, but a clinical response can be expected in only small proportion patients. The aim this study was to define molecular markers cetuximab therapy panel carcinoma cell lines.Eleven lines were investigated antiproliferative based on [(3)H]thymidine incorporation. A variety markers, including EGFR expression, phosphorylation, and gene amplification, as well expression other receptors, their...
BACKGROUND Patients with prostate cancer and their providers face uncertainty as they consider adjuvant radiotherapy (ART) or salvage (SRT) after undergoing radical prostatectomy. The authors prospectively evaluated the impact of Decipher test, which predicts metastasis risk prostatectomy, on decision making for ART SRT. METHODS A total 150 patients who were considering 115 SRT enrolled. Providers submitted a management recommendation before processing test again at time receipt results....
We defined the growth rate and reviewed our experience in surgical management of growing teratoma syndrome patients with nonseminomatous germ cell tumors.Nine were clinically diagnosed at center from 1980 to 2003. The defining criteria metastatic mass retroperitoneum or other site consisting entirely mature detected on serial abdominal/pelvic imaging during chemotherapy, a significant decrease normalization tumor markers.Precise radiological measurements retroperitoneal masses available for...
Expression of various members the ErbB family (epidermal growth factor receptor/ErbB-1, ErbB-2, ErbB-3 and ErbB-4) is associated with disease stage survival in patients urothelial carcinoma. We examined correlation receptor expression progression carcinoma survival.A tissue array was constructed from 248 archival paraffin blocks quality control studies were ascertained. The microarray stained for epidermal receptor, ErbB-4, analyzed using an automated reader. Patient data included grade,...
To evaluate the impact of a genomic classifier (GC) test for predicting metastasis risk after radical prostatectomy (RP) on urologists' decision-making about adjuvant treatment patients with high-risk prostate cancer.Patient case history was extracted from medical records each 145 pT3 disease or positive surgical margins (PSMs) RP treated by six high-volume urologists, five community practices. GC results were available 122 (84%) these patients. US board-certified urologists (n = 107)...
PURPOSE Germline genetic testing (GT) is important for prostate cancer (PCA) management, clinical trial eligibility, and hereditary risk. However, GT underutilized there a shortage of counselors. To address these gaps, patient-driven, pretest education webtool was designed studied compared with traditional counseling (GC) to inform strategies expanding access services. METHODS Technology-enhanced acceleration germline evaluation therapy (TARGET) multicenter, noninferiority, randomized...
Abstract Activation of the epidermal growth factor receptor (EGFR) and downstream signaling pathways, such as phosphatidylinositol-3 kinase/Akt Ras/mitogen-activated protein kinase (MAPK), have been implicated in causing resistance to EGFR-targeted therapy solid tumors, including urogenital tumors. To investigate mechanism EGFR inhibition bladder cancer, we compared tyrosine inhibitor (Gefitinib, Iressa, ZD1839) with respect its inhibitory effects on three kinases situated EGFR: MAPK, Akt,...
Abstract We characterized the effects of small molecule epidermal growth factor receptor (EGFR) inhibitor gefitinib (ZD1839, Iressa) on cell proliferation in a panel 17 human bladder cancer lines. Gefitinib inhibited DNA synthesis concentration-dependent fashion 6 Growth inhibition was associated with p27Kip1 accumulation and decreased cyclin-dependent kinase 2 activity. also baseline EGFR, AKT, extracellular signal-regulated (ERK) phosphorylation EGFR-dependent cells maintained serum-free...
The biopsy based 17-gene GPS was clinically validated to predict the likelihood of adverse surgical pathology in men with NCCN® very low, low or low-intermediate risk prostate cancer. We performed a prospective study assess impact incorporating into treatment recommendations 3 high volume urology practices.Men newly diagnosed cancer meeting specific NCCN criteria were prospectively enrolled trial. Biopsy tissue analyzed. Urologists indicated on questionnaires administered before and after...